All News
Vaccine Success is Limited in Rheumatoid Arthritis
Numerous guidelines (ACR, ACIP/CDC, ATS, NICE) all call for timely vaccinations in patients with rheumatoid arthritis (RA) and those receiving immunosuppressives or biologics.
Read Article
RheumNow Week in Review - 15 April 2016
Video recap of highlights from this week at RheumNow.com.
Read Article
Biosimilar Reports - April 2016
Major advances in biosimilars have occurred in the last three months, beginning with the FDA Arthritis Advisory Committee voting 21-3 to approve Celltrion’s Inflectra (CT-P13) and ending with the recent approval of Inflectra (generically referred to as infliximab dyyb).
Read Article
Population-Based TB Risk and Prevention with RA and Biologics
In a retrospective cohort comparison study, 42,180 rheumatoid arthritis (RA) patients were compared 1:4 with 168,000 normal controls to examine the incidence of new tuberculosis in Taiwan. The RA population included those receiving csDMARDs (36,162), etanercept (3,577), adalimumab (1,67
Read Article
March 2016 Top Social Media News
In March 2016, RheumNow published 82 social media “tweets” regarding news, research and teaching points that impact the rheumatology community. These feeds had a reach (impressions) of 86,400 with, 76 mentions, and over 2700 visits to learn on RheumNow.com.
Read Article
RheumNow Week in Review - 8 April 2016
Dr. Jack Cush reviews the rheumatology highlights from the news, media, and journals from this past week:
Read Article
FDA Biosimilar Approval of Inflectra Viewed as a Milestone Advance
On February 9th, the Food and Drug Administration (FDA) Arthritis Advisory Committee voted 21-3 in favor of approving the infliximab biosimilar, CT-P13/Inflectra, for use in all of infliximab's indications.
Read Article
Biologics Are Safe When Used During Pregnancy in IBD
This is a reposting of an earlier report on RheumNow that includes additional commentary from Dr. Sunada Kane, a gastroenterologist at the Mayo Clinic who specializes in both inflammatory bowel disease (IBD) and pregnancy.
Read Article
First Head-to-Head TNF Trial Ends in a Draw
Comparative efficacy trials may be the best way to make informed treatment choices in a sea of treatment options for rheumatoid arthritis (RA). Recent years have seen impressive head-to-head (H2H) clinical trials for RA, including AMPLE (abatacept vs.
Read Article
The Week in Review 18 March 2016
See the highlights from the past week that appeared on RheumNow.com, and watch Dr. Jack Cush as he reviews each of them.
Read Article
TNF Inhibitors Increase Perioperative Infection Risk
The use of tumour necrosis factor α inhibitors (TNFis) at the time of major surgery has been a challenge for surgeons, rheumatologists and those wishing to develop evidence-based guidelines for this clinical scenario.
Read Article
ACR Invites Comment on Perioperative Management Guidelines
The ACR is inviting members and rheumatologists to comment on their proposal to develop recommendations for the "Perioperative Management of Rheumatic Disease Medications in Total Joint Arthroplasty of the Hip and Knee".
Read Article
Biosimilars Reviewed by Expert Panel
As the number of biosimilars in development keeps on growing, reaching nearly 700 products to date, demand for data from randomized controlled trials (RCTs) and an understanding of these new biologics is peaking the interest of many.
Read Article
TNF Inhibition and Heart Failure
Clinicians often face the issue of using a TNF inhibitor (TNFi) in patients with heart failure or cardiac disease. Here are the facts and data necessary to make a cogent decision to use or avoid TNFi.
Read Article
Less Treatment, Responses and Safety in Elder-Onset Rheumatoid Arthritis
A recent review compared elderly-onset rheumatoid arthritis (EORA) to those with younger-onset rheumatoid arthritis (YORA) to assess treatment responses and safety issues with biologics and DMARDS. EORA is generally defined as the onset of rheumatoid arthritis after age 60 years.
Read Article
RA Flares Common After Anti-TNF Withdrawal
The risk of a flare increased by more than three-fold over 1 year when patients with longstanding rheumatoid arthritis (RA) in remission, or with stable low disease activity, stopped their anti-tumor necrosis factor (TNF) treatment, Dutch researchers reported.
Read Article
RWCS 2016 – Rheumatoid Review, Psoriatic Arthritis and Medical Marijuana
The Rheumatology Winter Clinical Symposia launched its 9th annual conference yesterday in Maui. Highlights of this meeting will be covered by RheumNow from Wednesday 2/10 till Saturday 2/13.
Rheumatoid Arthritis Year in Review
Read Article
